TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Cynata Therapeutics Limited ( (AU:CYP) ).
Cynata Therapeutics Limited announced an investor webinar hosted by CEO Dr. Kilian Kelly, aimed at providing updates on the company’s activities and key projects. The webinar reflects Cynata’s commitment to engaging with shareholders and stakeholders, offering insights into its ongoing clinical trials and the potential impact of its Cymerus™ technology on the regenerative medicine industry.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. It focuses on developing therapies using its proprietary Cymerus™ stem cell platform technology, which utilizes induced pluripotent stem cells to economically manufacture cell therapy products at a commercial scale. The company has shown positive results in Phase 1 clinical trials for its product candidates in treating conditions like steroid-resistant acute graft versus host disease and diabetic foot ulcers, with ongoing trials for other diseases.
Average Trading Volume: 203,407
Technical Sentiment Signal: Buy
Current Market Cap: A$61.74M
For detailed information about CYP stock, go to TipRanks’ Stock Analysis page.